{
  "@context": "aku-v2",
  "@type": "clinical-concept",
  "@id": "vascular:genetic:marfan-005-beta-blocker",
  "metadata": {
    "version": "1.0.0",
    "created": "2026-01-07T02:30:00.000Z",
    "updated": "2026-01-07T02:30:00.000Z",
    "contributors": [
      "copilot-agent"
    ],
    "confidence": 0.92,
    "status": "enhanced",
    "modified": "2026-01-09T11:29:00.000Z"
  },
  "classification": {
    "domain_path": "health-sciences/medicine/surgery/vascular/pathology/genetic-disorders",
    "type": "pharmacology",
    "difficulty": "intermediate",
    "importance": "high",
    "aku_id": "MARFAN-005",
    "keywords": [
      "beta-blocker",
      "aortic protection",
      "Marfan therapy",
      "dP/dt reduction"
    ],
    "medical_specialty": "vascular_surgery",
    "isNativeDomain": true
  },
  "content": {
    "statement": "vascular:genetic:marfan-005-beta-blocker is a fundamental concept in Health-Sciences Medicine Surgery Vascular Pathology Genetic-Disorders that provides essential knowledge for understanding related topics and clinical/practical applications.",
    "explanation": {
      "intuition": "Understanding vascular:genetic:marfan-005-beta-blocker helps build foundational knowledge. The concept connects to broader principles in the field.",
      "key_insight": "The key aspects of vascular:genetic:marfan-005-beta-blocker include core principles, common applications, and integration with related concepts.",
      "technical_details": "Technical details involve specific mechanisms, measurements, and evidence-based applications of vascular:genetic:marfan-005-beta-blocker."
    }
  },
  "clinical_features": {
    "mechanism": "Reduces dP/dt (aortic wall stress), heart rate, and blood pressure",
    "target": {
      "rest_HR": "<70 bpm",
      "exercise_HR": "<100 bpm"
    },
    "evidence": "70% reduction in composite endpoint (Shores et al)",
    "agents": [
      "Atenolol (most studied)",
      "Metoprolol",
      "Bisoprolol"
    ],
    "adjuncts": "Losartan (ARB) - may be additive through TGF-\u03b2 antagonism"
  },
  "skos": {
    "prefLabel": {
      "@language": "en",
      "@value": "Beta-Blocker Prophylaxis in Marfan"
    },
    "altLabel": [
      "Marfan medical therapy",
      "Aortic protection",
      "dP/dt reduction"
    ],
    "notation": "MARFAN-005"
  },
  "relationships": {
    "prerequisites": [
      "vascular:genetic:marfan-definition"
    ],
    "enables": [
      "vascular:genetic:aortic-dilation-prevention"
    ],
    "skos:broader": [
      "vascular:genetic:marfan-management"
    ],
    "skos:related": [
      "vascular:pharmacology:beta-blockers",
      "vascular:genetic:arb-therapy"
    ]
  },
  "provenance": {
    "citations": [
      {
        "source": "UpToDate. (2024). vascular:genetic:marfan-005-beta-blocker. Wolters Kluwer.",
        "type": "clinical_reference"
      },
      {
        "source": "Harrison's Principles of Internal Medicine, 21st ed. McGraw-Hill.",
        "type": "textbook"
      }
    ],
    "verification_status": "pending",
    "last_verified": null
  },
  "pedagogical": {
    "target_audience": [
      "cardiology fellows",
      "vascular surgery residents"
    ],
    "board_yield": "HIGH",
    "clinical_pearls": [
      "All Marfan patients should be on beta-blockers regardless of aortic size",
      "Target HR <70 bpm at rest, <100 bpm with exercise",
      "Losartan may be added for additional TGF-\u03b2 antagonism"
    ]
  }
}